Kezar Life Sciences (KZR) Accounts Payables (2021 - 2025)
Kezar Life Sciences (KZR) has disclosed Accounts Payables for 5 consecutive years, with $507000.0 as the latest value for Q4 2025.
- Quarterly Accounts Payables fell 86.11% to $507000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $507000.0 through Dec 2025, down 86.11% year-over-year, with the annual reading at $507000.0 for FY2025, 86.11% down from the prior year.
- Accounts Payables hit $507000.0 in Q4 2025 for Kezar Life Sciences, down from $911000.0 in the prior quarter.
- In the past five years, Accounts Payables ranged from a high of $8.3 million in Q4 2023 to a low of $507000.0 in Q4 2025.
- Historically, Accounts Payables has averaged $2.7 million across 5 years, with a median of $2.3 million in 2022.
- Biggest five-year swings in Accounts Payables: skyrocketed 232.84% in 2023 and later plummeted 86.11% in 2025.
- Year by year, Accounts Payables stood at $2.0 million in 2021, then increased by 22.24% to $2.5 million in 2022, then surged by 232.84% to $8.3 million in 2023, then plummeted by 55.75% to $3.7 million in 2024, then tumbled by 86.11% to $507000.0 in 2025.
- Business Quant data shows Accounts Payables for KZR at $507000.0 in Q4 2025, $911000.0 in Q3 2025, and $1.2 million in Q2 2025.